Diagnosis and therapy for advanced esophageal cancer

Current Opinion in Gastroenterology

Volumn 19, Issue 4, 2003, Pages 400-405

  Watson, Anthony ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cancer; Esophagus; Treatment

Indexed keywords

ADRENALIN; ALCOHOL; ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN; PACLITAXEL; VINBLASTINE;

ADVANCED CANCER; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; LASER COAGULATION; MUCOSA INFLAMMATION; NAUSEA; REVIEW; SIDE EFFECT; STENT;

EID: 0038337790     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200307000-00013     Document Type: Review

References (62)

1. Nguyen P, Feng JC, Chang KJ: Endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration (FNA) of liver lesions. Gastrointest Endosc 1999, 50:357-361.
2. Wakelin SJ, Deans C, Crofts TJ, et al.: A comparison of computerised tomography, laparoscopic ultrasound and endoscopic ultrasound in the preoperative staging of oesophago-gastric carcinoma. Eur J Radiol 2000, 41:161-167.
3. Watson A: Surgical management of carcinoma of the oesophagus. In: Upper Digestive Surgery. Edited by Taylor TV, Watson A, Williamson RCN. London: WB Saunders, 1999:216-245.
4. Vazquez-Sequerios E, Norton ID, Clain JE, et al.: Impact of EUS-guided fine needle aspiration on lymph node staging in patients with esophageal carcinoma. Gastrointest Endoscoc 2001, 53:751-757.
5. Rice TW, Adelstein DJ: Precise clinical staging allows treatment modification of patients with esophageal carcinoma. Oncology 1997, 11:58-62.
6. Siewert JR, Holscher AH, Dittle HJ: Preoperative staging and risk analysis in oesophageal carcinoma. Hepatogastroenterology 1990, 37:382-387.
7. Roder JD, Busch R, Stein HJ, et al.: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous carcinoma of the esophagus. Br J Surg 1994, 81:410-413.
8. Eloubeidi MA, Wallace MB, Hoffman BJ, et al.: Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg 2001, 72:212-220.
9. Watson A: Operable esophageal cancer: current results from the West. World J Surg 1994, 18:361-366.
10. Ide H, Nakamura T: Hayashi K, et al.: Esophageal squamous cell carcinoma: pathology and progress. World J Surg 1994, 18:321-330.
11. Lerut T, Flamen P, Ectors N, et al.: Histopathological validation of lymph node staging with FDG-PET in cancer of the esophagus and gastro-esophageal junction. Ann Surg 2000, 232:743-752.
12. Choi JY, Lee KH, Shim YM, et al.: Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG-PET. J Nucl Med 2000,41:808-815.
13. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinoma of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001, 19:3058-3066.
14. Kato H: Kuwano H, Nakajima M, et al.: Usefulness of positron emission tomography for assessing the response of neoadjuvant chemo-radiotherapy in patients with esophageal cancer. Am J Surg 2002, 184:279-283. A comparison of PET against CT and esphagography (but not EUS) confirming its superiority in correlating response both in tumor length and histology with PET uptake.
15. Isono K, Sato H, Nakayama K: Result of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991,48:411-415.
16. Perracchia A, Ruol A, Bardini R, et al.: Lymph node dissection for cancer of the thoracic oesophagus: how extended should it be? Analysis of personal data and review of the literature. Dis Esophagus 1992, 5:69-73.
17. Kelsen DP, Ginsberg R, Pajak TF, et al.: Chemotherapy followed by surgery compared with surgery alone for localised esophageal cancer. N Engl J Med 1998, 339:1979-1984.
18. Clark P. Surgical resection with or without pre-operative chemotherapy in oesophageal cancer: an updated analysis of a randomised controlled trial conducted by the UK Medical Research Council Upper GI tract Cancer Group [abstract]. Proc ASCO 2001, 20:502.
19. Ross P, Norman A, Cunningham D, et al.: A prospective randomised trial of protracted venous infusion (PVI) 5-FU with or without mitomycin C (MMC) in advanced colorectal cancer. Ann Oncol 1997, 8:95-101.
20. Ross P, Nicholson M, Cunningham D, et al.: Prospective randomised trial comparing mitomycin, cisplatin and protracted venous infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002, 20:1996-2004. A large (580 patients) randomized study confirming the superiority of ECF (epirubicin, cisplatin, and 5FU) from the standpoints of efficacy, toxicity, and quality of life and concluding that this should be one of the reference regimens in the treatment of advanced esophageal cancer.
21. Safran H: Gaissert H, Akerman P, et al. Paclitaxel, cisplatin and concurrent radiation for esophageal cancer. Cancer Invest 2001, 19:1-7.
22. Polee MB, Eskins FALM, van der Burg MEL: Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced esophageal cancer. Br J Cancer 2002, 86:669-673. Phase II study of the relatively new paclitaxel combined with cisplatin, with encouraging results and good patient tolerance, setting the scene for trials in the neoadjuvant setting.
23. Ajani JA, Fairweather J, Pisters PW, et al.: Phase II study of CPT-11 plus cisplatin in patients with advanced gastric and GE junction carcinoma [abstract]. Proc ASCO 1999, 18:927.
24. Anderson S, Ilson D, Bains M, et al.: Phase I trial of cisplatin and escalating dose irinotecan given weekly with concurrent radiation in locally advanced esophageal cancer [abstract]. Proc ASCO 2001, 20:629.
25. Herskovic A, Martz LK, Al-Sarraf M, et al.: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992, 326:1593-1598.
26. Leichman L, Herskovic A: Leichman CG, et al.: Preoperative therapy for squamous cell cancer of the esophagus. J Clin Oncol 1987, 5:365-370.
27. Forastiere AA, Orringer MB, Perez-Tamayo C, et al.: Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993, 11:1118-1123.
28. Bosset JE, Gignoux M, Triboulet JP, et al.: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997, 337:161-167.
29. Urba SG, Orringer MB, Turrisi A, et al.: Randomised trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001, 19:305-313.
30. Walsh TN, Noonan N: Hollywood D, et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996, 335:462-467.
31. Rice TW, Blackstone EH, Adelstein DJ, et al.: N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 2001, 122:454-464.
32. Gill PG, Denham JW, Jamieson GG, et al.: Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery. J Clin Oncol 1992, 10:1037-1043.
33. Denham JW, Burmeister BHH, Lamb DS, et al.: Factors influencing outcome following radio-chemotherapy for esophageal cancer. Radiother Oncol 1996, 40:31-43.
34. Chan K, Morrill S: Freeman D Jr, et al.: Bi-modality (chemoradiation) versus tri-modality (chemoradiation followed by surgery) treatment for carcinoma of the esophagus. Dis Esophagus 2001, 15:202-207.
35. Cooper JS, Guo MD, Herskovic A, et al.: Chemoradiotherapy of locally advanced esophageal cancer: long term follow up of a prospective randomised trial (RTOG 85-01). JAMA 1999, 281:1623-1627.
36. Ilson DH: New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002, 4:213-221. An excellent comprehensive review of the recent advances in all aspects of management of esophageal cancer.
37. Kishi K, Doki Y, Miyata HH, et al.: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 2002, 89:597-603. A study of the utility of p53, metallothionein, and CDC25B expression in predicting response to chemoradiation in terms of pathologic response and survival. p53- and metallothionein-positive tumors had a poor response to chemoradiation, whereas strong CDC25B expression was associated with a good response.
38. Yano M: Tsujinaka T, Shiozaki H, et al.: Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus. J Surg Oncol 1999, 70:25-32.
39. Ikeda K, Isheda K, Sato N, et al.: Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus 2001, 14:197-201.
40. Segalin A, Little AG, Ruol A, et al.: Surgical and endoscopic palliation of esophageal carcinoma. Ann Thorac Surg 1989, 48:267-271.
41. Whouley BP, Law S: Murthy SC, et al.: The Kirschner operation in unresectable esophageal cancer. Arch Surg 2002, 137:1228-1232.
42. Aoki T, Osaka Y, Takagi Y, et al.: Comparative study of self-expandable metallic stent and bypass surgery for inoperable esophageal cancer. Dis Esophagus 2001, 14:208-211.
43. Watson A: Self-expanding metal oesophageal endoprosthesis: which is best? Euro J Gastroenterol Hepatol 1998, 10:363-365.
44. Knyrim K, Wagner HJ, Bathge N, et al.: A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 1993, 329:1302-1307.
45. Hills KS, Chopra KB, Pal A, et al.: Self-expanding metal oesophageal endoprostheses covered and uncovered: a review of 30 cases. Eur J Gastroenterol Hepatol 1998, 5:367-370.
46. Tytgat GNJ, den Hartog Jager FC, Bartelsman JF: Endoscopic prosthesis for advanced esophageal cancer. Endoscopy 1986, 18:32-39.
47. Kozarek RA, Ball TJ, Brandabur JJ, et al.: Expandable versus conventional esophageal prostheses: easier insertion may not preclude subsequent stent-related problems. Gastrointest Endosc 1996, 43:204-208.
48. Cwikiel W, Tranberg KG, Cwikiel M, et al.: Malignant dysphagia; palliation with esophageal stents: long-term results in 100 patients. Radiology 1998, 207:513-518.
49. Miwa K, Mitsuoka M, Tayama S, et al.: Successful airway stenting using silicone prosthesis for esophago-bronchial fistula. Chest 2002, 122:1485-1487. First report of bronchial compression caused by esophagobronchial fistula 6 months after SEMS insertion being successfully palliated for a further 4 months by insertion of a silicone endobronchial prosthesis.
50. Carter R, Smith JS, Anderson JR: Laser recanulization versus endoscopic intubation in the palliation of malignant dysphagia: a randomised prospective study. Br J Surg 1992, 79:1167-1170.
51. Loizou LA, Grigg D, Atkinson M, et al.: A prospective comparison of laser therapy and intubation in endoscopic palliation of malignant dysphagia. Gastroenterology 1991, 100:1303-1310.
52. Adam A, Ellul J, Watkinson AF, et al.: Palliation of inoperable esophageal cancer: a prospective randomised trial of laser therapy and stent placement. Radiology 1997, 202:344-348.
53. Dallal HHJ, Smith GD, Grieve DC, et al.: A randomised trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc 2001, 54:549-557.
54. Sargeant IR, Tobias JS, Blackman G, et al.: Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study. Gut 1997, 40:362-369.
55. Spencer GM, Theme SM, Blackman GM, et al.: Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study. Gut 2002, 50:224-227. A follow-up randomized trial to a previous one from the same group that documented the increased dysphagia-free interval from 5 to 9 weeks when laser was combined with external beam radiation. This study comparing the addition of brachytherapy to laser with laser alone showed an increase from 5 to 19 weeks. However, there was no difference in survival
56. Alexander P, Mayoral W, Reilly HF, et al.: Endoscopic Nd:YAG laser with aggressive multimodality therapy for locally advanced esophageal cancer. Gastroinest Endosc 2002, 55:674-679. A nonrandomized study comparing chemoradiation alone with chemoradiation plus laser therapy in advanced esophageal carcinoma. Relief of dysphagia occurred in 66% of the laser group compared with 42% in the reference group, and mean survival was 30.1 months vs 16.5 months in historical controls.
57. Sur M, Sur RK, Cooper K, et al.: Morphologic alterations in esophageal squamous cell carcinoma after preoperative high dose rate intraluminai brachytherapy. Cancer 1996, 77:2200-2205.
58. Sur RK, Levin CV, Rad FF, et al.: Prospective randomised trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma: an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys 2002, 53:127-133. Randomized study of two different dosage regimens of brachytherapy concluding that brachytherapy alone surpasses any other palliative modality, although no comparison was made in this study. Mean dysphagia-free interval was 7.1 months and mean survival 7.9 months, with no difference emerging between the two regimens studied.
59. Vikekanandam S, Reddy KS, Velevan K, et al.: External beam radiotherapy and intraluminal brachytherapy in advanced inoperable esophageal cancer. Am J Clin Oncol 2001, 24:128-130.
60. Carazzone A, Bonavina L, Segalin A, et al.: Endoscopic palliation of oesophageal cancer: results of a prospective comparison of Nd:YAG laser and ethanol injection. Eur J Surg 1999, 165:351-356.
61. Harbord M, Dawes RFH, Barr H, et al.: Palliation of patients with dysphagia due to advanced esophageal cancer by endoscopic injection of cisplatin/epinephrine injectable gel. Gastroinest Endosc 2002, 56:644-651.
62. Pyrhinen S, Kuitunen T, Nyandot P, et al.: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995, 71:587-591.